Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 19, 2017
DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, will hold a conference call to discuss an upda...
Sep 12, 2017
DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported on an update on the interim analysis of da...
Sep 6, 2017
DURHAM, N.C., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported that for the first time a patient in the o...
Aug 21, 2017
DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that an interim analysis of data from the ...
Aug 9, 2017
- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data in AGS-004 Program for the Treatment of HIV - ...
Jul 26, 2017
DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced immunogenicity data from a stud...
Jun 22, 2017
DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the closing o...
Jun 16, 2017
DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that it entered ...
May 10, 2017
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today provided an update on the ADAPT trial, a r...
Apr 18, 2017
DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its random...
Feb 22, 2017
-Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the A...
Feb 13, 2017
DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the comp...
Feb 6, 2017
DURHAM, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the company...
Jan 19, 2017
DURHAM, N.C., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today the completion ...
Dec 14, 2016
DURHAM, N.C., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today that it...
Dec 13, 2016
DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of...
Dec 7, 2016
DURHAM, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported highlights from t...
Dec 1, 2016
DURHAM, N.C., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that registration is open for the company'...
Nov 29, 2016
DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presenting at the E...
Nov 18, 2016
DURHAM, N.C., Nov. 18, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, and its partner Cellthera Pharm ("Cellthera"), a subsidiar...
Nov 14, 2016
DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company is presenting ...
Nov 14, 2016
- Dr. Richard D. Katz Joined as Chief Financial Officer -- Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV -- Investor Day Sche...
Nov 11, 2016
DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be participating in ...
Nov 10, 2016
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be pre...
Nov 7, 2016
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's third quarter 2016 fina...
Nov 3, 2016
Two advanced kidney cancer patients from a Phase 2 clinical trial maintain ongoing control of metastatic disease seven years after initiation of treatment with AGS-003 in combination with sunitinib. DURHAM, N.C., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. ...
Nov 2, 2016
DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company is participating in the...
Oct 26, 2016
DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced Jeff Abbey, the company's president and ch...
Oct 19, 2016
Event to be held at NASDAQ MarketSite in New York City from 8:00-11:00 a.m. Eastern Time. Immunology and kidney cancer experts to review the company's individualized immunotherapies based on the Arcelis® technology platform and discuss the treatment landscape. ...
Oct 14, 2016
DURHAM, N.C., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presen...
Oct 3, 2016
DURHAM, N.C., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presenting ...
Sep 1, 2016
DURHAM, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will participate...
Aug 10, 2016
- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29.8 million Second Tranche of March 2016 Financing - - Raised Gross Proceeds of $50.0 million in Follow-on ...
Aug 4, 2016
DURHAM, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's second quarter 20...
Jul 28, 2016
DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the pricing o...
Jul 27, 2016
DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it inten...
Jul 14, 2016
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the combination of the latency-reversing drug, vorinostat, and AGS-004, the company's investigational immunotherapy based on the Arcelis® technology platform. DURHAM, N.C., Ju...
Jul 11, 2016
DURHAM, N.C., July 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform...
Jun 29, 2016
DURHAM, N.C., June 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it...
Jun 27, 2016
DURHAM, N.C., June 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the comp...
Jun 15, 2016
DURHAM, N.C., June 15, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it is partne...
Jun 13, 2016
Positive outcome triggers the second tranche of the Company's previously announced financing agreement Argos Therapeutics to host conference call with the trial's co-principal investigator, Dr. Robert Figlin, on Thursday, June 16, 2016 at 4:30 pm EDT ...
Jun 8, 2016
DURHAM, N.C., June 08, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the comp...
May 12, 2016
- Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring Committee - - Dr. Lee F. Allen joined as Chief Medical Office...
May 11, 2016
DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the ...
May 5, 2016
DURHAM, N.C., May 05, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's first quarter 2016...
Apr 7, 2016
DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the...
Mar 29, 2016
DURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.Media c...
Mar 29, 2016
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 —  - Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 Following Data Reviews in June and December 2015 - ...
Mar 23, 2016
DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the initiation of an...
Mar 22, 2016
DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's fourth quarter and full-year 2015...
Mar 22, 2016
DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company ...
Mar 18, 2016
DURHAM, N.C., March 18, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and HIV based on the Arcelis® technology platform, today announced the company wil...
Mar 17, 2016
DURHAM, N.C., March 17, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company ...
Mar 7, 2016
DURHAM, N.C., March 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it has ...
Jan 20, 2016
DURHAM, N.C., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Lee F. Allen, MD, PhD, has joined the ...
Dec 10, 2015
DURHAM, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced its independent data monitoring committee (ID...
Dec 9, 2015
DURHAM, N.C., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced the company will participate in the ROTH Immuno-Oncology Corporate Access ...
Nov 16, 2015
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 - - Established Scientific Advisory Board - - Early stage RCC trial of AGS-003 initiated at Roswell Park Cancer Institute - - Conference Call and Webcast Today, November 16th, at 8:30 a.m. ET - DURHAM, N.C., Nov. 16, 2015 (GLOBE NEWSWIR...
Nov 9, 2015
DURHAM, N.C., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's third quarter 2015 financial results will be released b...
Nov 6, 2015
DURHAM, N.C., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced the company will present at Alliance for Regenerative Medicine's 3rd Annua...
Nov 5, 2015
DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced the company will present at the 3rd International mRNA Health Conference b...
Oct 5, 2015
DURHAM, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced the company will host a special briefing conference call focused on the current ...
Oct 2, 2015
DURHAM, N.C., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced that Shawn Leland, PharmD, RPh, Argos's director of corporate development and st...
Sep 23, 2015
DURHAM, N.C., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced the appointment of Robert F. Carey to the company's board of directors. ...
Sep 8, 2015
DURHAM, N.C., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced the company will participate in the FBR Second Annual Healthcare Conference bei...
Sep 1, 2015
DURHAM, N.C., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced the company will present at the Stem Cells and Regenerative Medicine Congress b...
Aug 24, 2015
DURHAM, N.C., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced that it has been issued U.S. Patent No. 9,085,807 by the United States Patent a...
Aug 12, 2015
- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 - - Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 - - Established Scientific Advisory Board - - Conference Call and Webcast Today, August 12th, at 4:30 p.m. ET - ...
Aug 10, 2015
DURHAM, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the initiation of a single-center pilot clini...
Aug 5, 2015
DURHAM, N.C., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the Company's second quarter 2015 financial result...
Jul 21, 2015
DURHAM, N.C., July 21, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the formation of the company's first Scientif...
Jul 17, 2015
The company's director of molecular biology to participate in roundtable discussion at the "Towards an HIV Cure" symposium DURHAM, N.C., July 17, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Jul 15, 2015
DURHAM, N.C., July 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the pivotal phase 3 ADAPT clinical trial of AGS...
Jun 16, 2015
DURHAM, N.C., June 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Jeff Abbey, president and CEO, will present at the ...
Jun 15, 2015
DURHAM, N.C., June 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that John D. Menditto has joined the Company as...
Jun 4, 2015
DURHAM, N.C., June 4, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced an independent data monitoring committee (IDMC) ...
May 29, 2015
DURHAM, N.C., May 29, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced that Mr. Jeffrey D. Abbey, the company's president and...
May 20, 2015
DURHAM, N.C., May 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Dr. Charles Nicolette, the company's chief ...
May 14, 2015
-Interim data analyses from the phase 3 ADAPT trial at approximately 25% of events expected during ASCO Annual Meeting- - Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET - DURHAM, N.C., May 14, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and comm...
May 13, 2015
DURHAM, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that more than 1,000 tumor samples have been col...
May 8, 2015
DURHAM, N.C., May 8, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Christine Fernandez, RN, MSN/Ed, OCN, who c...
May 7, 2015
DURHAM, N.C., May 7, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform, today announced that the Company's first quarter 2015 financial results will...
Apr 23, 2015
DURHAM, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company received the Economic Development...
Apr 21, 2015
DURHAM, N.C., April 21, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that data from a Phase 2 clinical trial of AG...
Apr 20, 2015
DURHAM, N.C., April 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company will present an update on the ong...
Apr 14, 2015
DURHAM, N.C., April 14, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, and Lummy (Hong Kong) Co. Ltd., a wholly owned subsidiary of...
Apr 7, 2015
DURHAM, N.C., April 7, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform, today announced that Jeff Abbey, president and chief executive officer, wi...
Apr 1, 2015
DURHAM, N.C., April 1, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that the NIH Division...
Mar 30, 2015
- Full Enrollment and Randomization in the Pivotal Phase 3 ADAPT Trial of AGS-003 for Metastatic Renal Cell Carcinoma (mRCC) Expected by the end of 2nd Quarter - - First Interim Analysis from the ADAPT Trial by IDMC Expected in the 2nd Quarter - - Conference Call and Webcast Today, March 30th, at 4:30 p.m. ET - DURHAM, N.C.,...
Mar 20, 2015
DURHAM, N.C., March 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced Dr. Mark DeBenedette,...
Mar 16, 2015
DURHAM, N.C., March 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform, today announced that the Company's fourth quarter and year-end 2014 finan...
Mar 4, 2015
DURHAM, N.C., March 4, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chi...
Feb 27, 2015
DURHAM, N.C., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that an update on the company's Phase 3 ADAPT ...
Feb 24, 2015
DURHAM, N.C., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Joan C. Winterbottom will join the compan...
Feb 2, 2015
DURHAM, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chie...
Jan 23, 2015
DURHAM, N.C., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that Dr. Fred Miesowic...
Jan 22, 2015
DURHAM, N.C., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the company's director...
Jan 20, 2015
DURHAM, N.C., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that Dr. Charles Nicol...
Jan 9, 2015
Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies. Company to host conference call and webcast today at 8:30 a.m. ET. DURHAM, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and...
Jan 6, 2015
DURHAM, N.C., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chie...
Jan 6, 2015
DURHAM, N.C. and AURORA, Ohio, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced a coll...
Nov 25, 2014
DURHAM, N.C., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chi...
Nov 24, 2014
DURHAM, N.C., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the company has been h...
Nov 13, 2014
DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today reported financial results for the third qua...
Nov 13, 2014
DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced the appointment of Phili...
Nov 12, 2014
DURHAM, N.C., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chi...
Nov 6, 2014
DURHAM, N.C., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that the Company's third quarter 20...
Nov 5, 2014
SAN DIEGO, CA and DURHAM, NC - Nov. 5, 2014 - Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Argos Therapeutics Inc. (Nasdaq: ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cance...
Oct 22, 2014
- New 100,000 square foot facility supported by incentives from State of North Carolina, Durham County, City of Durham and North Carolina Biotechnology Center. William "Bill" Bell, Mayor, City of Durham, Micha...
Oct 3, 2014
State of the Art Facility Planned for Automated Production of Arcelis® Personalized Immunotherapies Project Supported by $9.5 Million in Incentives From State of North Carolina, Durham County and City of Durham DURHAM, N.C., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical c...
Oct 1, 2014
DURHAM, N.C., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chie...
Sep 30, 2014
DURHAM, N.C., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that it has entered in...
Sep 19, 2014
DURHAM, N.C., Sept. 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and ch...
Sep 18, 2014
DURHAM, N.C., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced it has recently surpassed fifty ...
Sep 8, 2014
DURHAM, N.C., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that the United States Patent and ...
Sep 3, 2014
DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and ch...
Aug 13, 2014
DURHAM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today reported financial results for the second q...
Aug 6, 2014
DURHAM, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company's second quarter ...
Jul 21, 2014
DURHAM, N.C., July 21, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has presented da...
Jun 11, 2014
DURHAM, N.C., June 11, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and ch...
Jun 5, 2014
DURHAM, N.C., June 5, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company will host a confe...
Jun 2, 2014
Results presented on May 30, 2014 at the ASCO Annual Meeting, show that intermediate risk mRCC patients had a median overall survival of 57.1 months, with 23 percent surviving for more than five years to date, including two patients in long-term remission following continued AGS-003 dosing.Argos to also present progress update on the pivotal ADAPT ...
May 28, 2014
DURHAM, N.C., May 28, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeffrey D. Abbey, president an...
May 27, 2014
DURHAM, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has been selected...
May 19, 2014
DURHAM, N.C., May 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief scientific offic...
May 15, 2014
DURHAM, N.C., May 15, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief operating office...
May 13, 2014
AGS-003 Phase 2 Long-Term Survival Data Update to be presented at ASCO AGS-004 Phase 2 HIV Eradication Trial in Adults Initiated Conference Call and Webcast Today, May 13th, at 4:30 p.m. ET DURHAM, N.C., May 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the develo...
May 12, 2014
Results from study of long-term survival in metastatic renal cell carcinoma patients treated with combination of AGS-003 plus sunitinib to be presented May 31; update on ADAPT Phase 3 trial to be presented June 2. DURHAM, N.C., May 12, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on th...
Apr 29, 2014
DURHAM, N.C., April 29, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's first quarter 2014 financial results will be released after market close on Tuesday, May 13, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answe...
Apr 7, 2014
DURHAM, N.C., April 7, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission. A copy of the Annual Report on Form 10-K is available to be viewed or downloaded from the Investors section of Argos's...
Apr 1, 2014
DURHAM, N.C., April 1, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company will be presenti...
Mar 31, 2014
DURHAM, N.C., March 31, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has been added t...
Mar 27, 2014
- AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - -    AGS-004-Induced Immune Responses Associated with a Longer Time to Viral Rebound - - $43.7 Million Raised in Initial Public Offering - - Conference Call and Webcast Today, March 27th, at 4:30 p.m. ET - DURHAM, N.C., March 27, 2014 (GLOBE NE...
Mar 21, 2014
DURHAM, N.C., March 21, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeffrey Abbey, president and chie...
Mar 19, 2014
DURHAM, N.C., March 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will be presenti...
Mar 17, 2014
DURHAM, N.C., March 17, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Doug Plessinger, vice presid...
Mar 14, 2014
DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these res...
Mar 4, 2014
DURHAM, N.C., March 4, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today presented data from clinical studies of AGS-...
Feb 7, 2014
DURHAM, N.C., Feb. 7, 2014 /PRNewswire/ -- Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Argos. In addition, the underwriters have an option for...
Jan 28, 2014
Nov 20, 2013
Nov 12, 2013
Nov 11, 2013
Sep 24, 2013
Sep 16, 2013
Aug 26, 2013
Aug 15, 2013
Jul 1, 2013
Jun 13, 2013
Jun 10, 2013
May 8, 2013
Apr 29, 2013
Mar 13, 2013
Mar 4, 2013
Feb 14, 2013
Jan 28, 2013
Jan 14, 2013
Nov 15, 2012
Nov 2, 2012
Sep 20, 2012
Sep 6, 2012
Sep 4, 2012
Jul 2, 2012
Jun 7, 2012
May 3, 2012
Apr 24, 2012
Feb 4, 2012
Jan 31, 2012
Oct 4, 2011
Jul 29, 2011
Jun 28, 2011
Jun 5, 2011
Jun 1, 2011
May 4, 2011
Apr 5, 2011
Jan 31, 2011
Page:
...
Next Last
 
= add release to Briefcase

Stock Quote

NASDAQ: ARGS
0.19
+ 0.01 (+5.71%)

Day High:
0.19

Day Low:
0.18

Volume:
3,701,714

4:00 PM ET on Sep 19, 2017
Delayed at least 20 minutes.

Tweets